Actively Recruiting
Rapid Assessment of Sentinel Lymph Node Metastasis Status Using a Pan-CK-targeting NIR-II Fluorescent Probe in Breast Cancer
Led by Yunnan Cancer Hospital · Updated on 2025-09-04
60
Participants Needed
1
Research Sites
95 weeks
Total Duration
On this page
Sponsors
Y
Yunnan Cancer Hospital
Lead Sponsor
X
Xiang'an Hospital of Xiamen University
Collaborating Sponsor
AI-Summary
What this Trial Is About
Breast malignant tumors are a serious threat to women's health, and the current treatment for breast malignant tumors is still dominated by surgery, but the problems faced by patients after surgery such as edema and tumor recurrence are still relatively common, and the high recurrence rate and the occurrence of postoperative complications are closely related to the removal of metastatic lymph nodes during surgery. Therefore, accurate assessment of sentinel lymph node (SLN) metastases is essential to determine the extent of axillary lymph node dissection (ALND) and minimize complications. In this study, we developed a new technique that can rapidly distinguish between metastatic lymph nodes and normal sentinel lymph nodes (SLNs) in breast cancer patients. Briefly, fresh tissue is incubated with the probe and imaged immediately after intraoperative sentinel lymph node resection to identify the metastatic status of SLN. The accuracy of fluorescence imaging is confirmed by pathological diagnosis.
CONDITIONS
Official Title
Rapid Assessment of Sentinel Lymph Node Metastasis Status Using a Pan-CK-targeting NIR-II Fluorescent Probe in Breast Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 to 75 years
- Presence of a breast nodule or mass considered resectable before surgery
- Diagnosed with breast cancer and scheduled for sentinel lymph node biopsy or axillary lymph node dissection
- Suitable candidate for surgery
- Able to give informed consent and participate in the consent process
You will not qualify if you...
- Unable to participate in the consent process
- Contraindications to surgery such as serious heart or lung disease or bleeding problems
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Yunnan Cancer Hospital, Kunming, Yunnan 650118
Kunming, Yunnan, China
Actively Recruiting
Research Team
J
Junhong Chen, Postgraduate
CONTACT
W
Weiling Chen, Doctor
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here